Enders, Philip ORCID: 0000-0002-9527-4957, Muether, Philipp S., Hermann, Manuel, Ristau, Tina and Fauser, Sascha (2015). LONG-TERM ALTERATIONS OF SYSTEMIC VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS IN PATIENTS TREATED WITH RANIBIZUMAB FOR AGE-RELATED MACULAR DEGENERATION. Retin.-J. Retin. Vitr. Dis., 35 (3). S. 454 - 459. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1539-2864

Full text not available from this repository.

Abstract

Purpose: To analyze long-term changes of systemic vascular endothelial growth factor (VEGF) levels in patients treated with ranibizumab for neovascular age-related macular degeneration. Methods: Sixty-one patients with neovascular age-related macular degeneration and 68 age-matched controls were included in the study. Patients were treated with ranibizumab on a pro re nata regimen. Plasma samples were collected before initiation of treatment and after 1 year (30 patients) or 2 years (31 patients) of treatment. Vascular endothelial growth factor was measured by Luminex microbead analysis. Results: At baseline, patients with neovascular age-related macular degeneration and controls did not differ significantly in VEGF levels (P = 0.062). There was a significant decline in systemic VEGF levels of 39.5% after 1 year (34.2 +/- 17.2 pg/mL to 20.7 +/- 14.0 pg/mL; P = 7.50 x 10(-5)) and of 46.7% after 2 years (40.4 +/- 24.1 pg/mL to 21.5 +/- 23.3 pg/mL; P = 2.48 x 10(-4)) of treatment. Patients with persistent activity of choroidal neovascularization showed a significantly smaller decrease of plasma VEGF levels than patients with dry intervals despite the higher number of injections (P = 0.048). Conclusion: In addition to immediate effects limited to days if not hours, ranibizumab also leads to long-term alterations of systemic VEGF to subnormal levels. Patients with persistent choroidal neovascularization activity showed a less pronounced VEGF decrease. Therefore, VEGF levels might be a useful marker for treatment response.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Enders, PhilipUNSPECIFIEDorcid.org/0000-0002-9527-4957UNSPECIFIED
Muether, Philipp S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hermann, ManuelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ristau, TinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fauser, SaschaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-411094
DOI: 10.1097/IAE.0000000000000320
Journal or Publication Title: Retin.-J. Retin. Vitr. Dis.
Volume: 35
Number: 3
Page Range: S. 454 - 459
Date: 2015
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Place of Publication: PHILADELPHIA
ISSN: 1539-2864
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
INTRAVITREAL INJECTION; PLASMA-LEVELS; BEVACIZUMAB; TRIALMultiple languages
OphthalmologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/41109

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item